HER-2 positive expression corresponding to score3+ (excluding equivocal score 2) in our study was detected in 5.3% of all cases; this was confirmed by several other studies with a positive expression in 0.5% to 49.6% in CRC [35–37], while this expression was not significantly associated with therapeutic response as reported by the study of Kwon et al. [38]. The gene discussed is ERBB2; the disease is colorectal carcinoma.